Sensitive spectrophotometric assay of simvastatin in pharmaceuticals using permanganate

Abstract

Two simple, sensitive, selective and inexpensive spectrophotometric methods are described for the determination of simvastatin (SMT) in bulk drug and in tablets using permanganate as the oxidimetric reagent. In method A, SMT is treated with a measured excess of permanganate in acetic acid medium and the unreacted oxidant is measured at 550 nm, whereas in method B the reaction is carried out in alkaline medium and the resulting manganate is measured at 610 nm. In method A, the amount of permanganate reacted corresponds to the SMT content and the absorbance is found to decrease linearly with the concentration; and in method B, the absorbance increases with concentration. The working conditions of assays were optimized, and the methods were validated according to the current ICH guidelines. Under optimum conditions, SMT could be assayed in the concentration ranges, 1.47 -17.67x10 -5 and 2.27 -27.18 x10 -6 mol/L by method A and method B, respectively. The calculated molar absorptivities are 3.2 x 10 3 and 2.5 x 10 4 L/mol/cm for method A and method B, respectively with corresponding Sandell sensitivity values of 0.0387 and 0.0178 µg/cm 2 . The limits of detection (LOD) and quantification (LOQ) have also been reported. Accuracy and precision for the assay were determined by calculating the intra-day and inter-day at three concentrations; the intra-day RSD was < 2% and the accuracy was better than 2.15 % (RE). The methods were applied successfully for the determination of SMT in tablet dosage form with a high percentage of recovery, good accuracy and precision, and without measurable interference by the excipients. The accuracy was further ascertained from placebo and synthetic mixture analysis and also from the spike-recovery method.Uniterms: Simvastatin assay. Spectrophotometry. Permanganate. Pharmaceutical products. Dois métodos espectrofotométricos simples, sensíveis, seletivos e baratos são descritos para a determinação de sinvastatina (SMT) a granel e em comprimidos, utilizando permanganato como reagente oxidimétrico. No método A, a SMT é tratada com excesso conhecido de permanganato em meio de ácido acético e o oxidante que não reage é medido a 550 nm, enquanto no método B, a reação é efetuada em meio alcalino e o manganato resultante é medido a 610 nm. No método A, a quantidade de permanganato que reage corresponde ao conteúdo de SMT e a absorbância diminui linearmente com o aumento da concentração; no método B, a absorbância aumenta com o aumento da concentração. As condições de trabalho do ensaio foram otimizadas e os métodos, validados de acordo com as normas do ICH. Sob condições ótimas, a SMT pode ser ensaiada nas faixas de concentração de 1,47-17,67x10-5 e de 2,27-27,18 x10 -6 mol/L pelo método A e B, respectivamente. As absortividades molares calculadas são 2 x 10 3 e 2,5 x 10 4 L/ mol/cm, respectivamente, para os métodos A e B, com os valores correspondentes de sensibilidade de Sandell de 0,0387 e 0,0178 µg/cm 2 . Os limites de detecção (LOQ) também foram relatados. A exatidão e a precisão do ensaio fo...

Validated green spectroscopic manipulation of area under the curve (AUC) for estimation of Simvastatin: Application to nano-structured lipid carriers and niosomal systems

“…Literature revealed reversed phase high performance liquid chromatography (RP-HPLC) methods for the analysis of SIM in different formulations in presence of co-formulated drugs, components and/or excipients [17][18][19][20][21] . In addition to HPLC methods, several spectroscopic approaches were reported for the analysis of SIM including colorimetric methods [22][23][24] , ultraviolet (UV) spectrophotometric methods [25][26][27][28] and chemometric methods 29,30 .…”

Validated green micellar electrokinetic capillary chromatography for simultaneous determination of simvastatin and sitagliptin phosphate binary mixture in pharmaceutical formulation

“…Simvastatin (SMV), official in 2004 U.S. Pharmacopoeia, is chemically named as (1S, 2S, 8S, 8aR)‐1,2,6,8,8a‐hexahydro‐1‐(2‐((2R,4R)‐tetrahyro‐4‐hydroxy‐6‐oxo‐2H‐pyran‐2‐yl)‐2,6‐dimethylnapthalen ‐8‐yl2,2‐dimethylbutanoate (Figure 1). It belongs to the well‐known class of statins; hypolipidemics (cholesterol lowering) [8]. This semi‐synthetic prodrug is transformed to its β‐hydroxyacid form that inhibits 3‐hydroxy‐ 3‐methylglutaryl coenzyme‐A reductase (HMGCoA) and thus decreases low‐density lipoprotein, triglycerides, and increases high‐density lipoproteins [9,10].…”